AACPN Applauds Connecticut Enactment of Public Act 26-108 Expanding Psychedelic-Assisted Therapy Research

The American Alternative Care Policy Network (AACPN) applauds Governor Ned Lamont and the Connecticut General Assembly following the enactment of Public Act 26-108 on May 27, 2026, legislation expanding Connecticut’s psychedelic-assisted therapy pilot program and reinforcing the state’s commitment to evidence-based mental health research involving emerging psychedelic-assisted therapies.

The law expands eligibility for participation in Connecticut’s medically supervised psychedelic-assisted therapy pilot program while continuing research partnerships through established academic and clinical institutions. The program focuses on emerging therapies involving substances such as psilocybin and MDMA within regulated clinical and research settings.

“Connecticut has demonstrated that serious conversations about psychedelic-assisted therapy can be grounded in medical research, patient safety, and scientific rigor,” said Amanda J. Parker, Director of Alternative Care Advocacy for AACPN. “This legislation reflects a responsible effort to expand research and prepare healthcare systems for potential future FDA-approved treatment pathways.”

“Far too many veterans continue to struggle with the invisible wounds of service,” said Adrian Bruneau, Director of Political & Public Affairs for AACPN and a Marine Corps veteran. “Supporting rigorous clinical research may help expand future treatment options for those who have sacrificed for our country.”

“Firefighters, law enforcement officers, EMS personnel, healthcare workers, and other first responders are routinely exposed to traumatic situations throughout their careers,” said John R. Gordon, Director of Healthcare Policy & External Affairs for AACPN and a volunteer first responder. “Research into emerging therapies may help expand future treatment options for those who spend their lives protecting others.”

AACPN noted that Connecticut’s action comes amid growing national discussion surrounding psychedelic-assisted therapy research, including increasing federal attention on PTSD, treatment-resistant depression, trauma recovery, and veterans’ mental health.

The organization said continued scientific research and clinical evaluation must remain central to future policy discussions involving psychedelic-assisted therapies.

AACPN will continue supporting responsible scientific research into alternative and integrative care approaches that may improve treatment outcomes for veterans, first responders, trauma survivors, and other Americans seeking safe, evidence-based healthcare options.